Table 1.
Clinical features of the studied subjects.
| Clinical feature | NMOSD (n=45) | RRMS (n=17) | CIS (n=14) | HC (n=20) | P value | ||
|---|---|---|---|---|---|---|---|
| NMOSD vs. RRMS | NMOSD vs. HC | RRMS vs. HC | |||||
| Female/male ratio | 6.5:1 | 1.4:1 | 2.5:1 | 9:1 | 0.02 | 0.53 | 0.08 |
| Age at study (year) | 40.9±12.8 | 31.2±9.3 | 46.4±17.3 | 44.7±9.8 | 0.01 | 0.25 | 0.06 |
| Age at onset (year) | 36.1±13.3 | 28.9±8.1 | 44.4±17.3 | – | 0.04 | – | |
| Disease duration (year) | 4.9±6.6 | 3.8±4.6 | 1.8±5.3 | – | 0.49 | – | |
| Relapse (time) | 3.4±2.1 | 2.2±0.9 | – | – | 0.03 | – | |
| EDSS score at the last visit | 3.4±2.0 | 2.4±1.1 | 2.4±1.2 | – | 0.06 | – | |
| Ratio of visual impairment (≤0.1/>0.1) | 9:36 | 1:16 | 6:8 | – | 0.17 | – | |
| Ratio of anti-AQP4-Ab positivity (±) | 34/6 | 0/10 | 0/5 | – | <0.0001 | – | |
| Ratio of autoantibody positivity (±) | 15/21 | 1/14 | 0/10 | – | 0.002 | – | |